Company: CERO
Filing Date: 2025-11-19
Form Type: 10-Q
Source: 0001213900-25-112619
Chunk: 31

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-11-19
Form: 10-Q
Item: Item 1
Chunk 31
---
 basic loss per share as these shares are not considered outstanding until vested. No unvested restricted
common stock awards were issued or outstanding during the nine months ended September 30, 2025 or the nine month period ended September
30, 2024.

NOTE 5 – PROPERTY AND
EQUIPMENT

Property and equipment, net, consisted of the
following as of September 30, 2025 and December 31, 2024:

    September 30,  
    December 31, 

    2025  
    2024 

    (Successor)  
    (Successor) 
  
    Laboratory equipment 
    $2,507,839  
    $2,507,839 
  
    Computers 
     38,323  
     38,323 
  
    Furniture 
     8,429  
     8,429 
  
    Total cost 
     2,554,591  
     2,554,591 
  
    Less: accumulated depreciation 
     (2,241,139) 
     (2,026,070)
  
    Property and equipment, net 
    $313,452  
    $528,521 

Successor depreciation expense
for the three months ended September 30, 2025 and 2024 was $69,354 and $113,855, and for the nine months ended September 30, 2025 and
for period from February 14, 2024 through September 30, 2024 Successor depreciation expense was $215,069 and $304,446, respectively. Predecessor
depreciation expense for the period January 1, 2024 through February 13, 2024 was $37,356.

13

NOTE 6 – ACCRUED LIABILITIES

Accrued liabilities consisted of the following as of September
30, 2025 and December 31, 2024:

    September 30,  
    December 31, 

    2025  
    2024 

    (Successor)  
    (Successor) 
  
    Employee-related liabilities 
    $4,415  
    $244,302 
  
    Accrued franchise taxes 
     78,448  
     78,448 
  
    Accrued legal expenses 
     40,000  
     593,825